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nonpigmented swordtail (Xiphophorus 
hellerii) parents, when backcrossed to 
swordtails, produce hybrids with phe-
notypes that segregate in an apparently 
Mendelian fashion, consistent with a 
two-gene inheritance model. In 1952, 
Breider hypothesized that melanomas 
developed in the susceptible pigmented 
Xiphophorus backcross hybrids as the 
result of the loss of a regulatory locus 
that inhibited genes controlling pigmen-
tation, anticipating the oncogene–tumor 
suppressor gene concept by almost two 
decades. Classical genetic recombina-
tion mapping subsequently established 
that a sex-linked pigmentation determin-
ing locus (Mdl) and an autosomal regu-
latory locus (R) were indeed involved 
in determining BC1 hybrid phenotypes, 
including melanoma susceptibility.
In the late 1980s and early 1990s, 
Schartl and colleagues published 
work that associated an EGFR-related 
gene, Xmrk, with the sex-linked Mdl 
locus (then called Tu). The molecular 
cloning and characterization of 
this oncogenic melanoma receptor 
kinase revolutionized the study of the 
Xiphophorus melanoma model and 
strengthened the concept of Xmrk as 
a dominant oncogene in the model, 
with R playing the role of a recessive 
tumor suppressor. The true identity 
of R has proven elusive, because the 
cloned candidate for this susceptibility 
locus, a homolog of the CDKN2 family 
called CDKN2AB, does not behave as 
predicted for a recessive tumor suppres-
sor. However, a number of complexities 
are revealed by studying other hybrid 
crosses available in Xiphophorus, and 
it is possible that R may be playing the 
role of a modifier of Xmrk activity rather 
than a frank suppressor, at least within 
Xiphophorus interspecies hybrids (see 
Butler et al., 2007, for a discussion of 
this point). In any event, there is abun-
dant evidence that Xmrk can behave 
as a dominant oncogene, specifically 
overexpressed in pigmented tissue 
and driving oncogenesis. In this issue, 
Schartl and colleagues express Xmrk as 
a transgene in the pigmented tissues of 
a fish other than Xiphophorus, called 
medaka, and demonstrate conclu-
sively that this gene is a powerful and 
dominant oncogene driving melanoma 
formation (Figure 1). Of greater interest, 
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Xmrk in Medaka:  
A New Genetic Melanoma Model
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Melanoma is the most lethal form of skin cancer, and its incidence is rising rapidly 
(Chin et al., 2006; Linos et al., 2009). Highly aggressive, metastatic melanoma is 
notoriously resistant to chemotherapy, and early detection is critical for surgical 
excision (Gray-Schopfer et al., 2007). A detailed knowledge of the cellular, 
molecular, and genetic events during melanoma progression is highly relevant to 
both diagnosis and the development of new therapies. Animal models, such as 
the one described in this issue by Schartl and colleagues, are important tools for 
identifying the genetic and environmental factors that contribute to melanoma 
development, as well as identifying and testing new therapeutic strategies.
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Xmrk, Xiphophorus, and  
melanoma genetics
Fish have long been used in biomedical 
research and are increasingly used as 
models of human disease. Fish can 
develop a wide range of cancers, includ-
ing neurofibromatosis, hematologi-
cal and liver cancers, and melanoma, 
among others (Bunton, 1996). The 
Xiphophorus hybrid melanoma was rec-
ognized in the 1920s as a genetically 
controlled tumor model and has been 
studied since then (Meierjohann and 
Schartl, 2006). In this melanoma model, 
interspecies hybrids between pigmented 
platyfish (Xiphophorus maculatus) and 
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in adult fish. Zebrafish and medaka 
can also be modified with transgenes, 
and expression of human cancer genes 
driven by tissue-specific promoters has 
led to the development of new models 
of cancer, including leukemias, pan-
creatic tumors, rhabdo myosarcoma, 
and melanoma.
a new Xmrk melanoma model
Oncogenic Xmrk in the Xiphophorus 
melanoma model provides a valuable 
opportunity to study melanoma can-
cer biology (Meierjohann and Schartl, 
2006), but the lack of genomic resources 
and transgenic technologies has meant 
that identification of genetic modifiers 
has been a significant obstacle in the 
Xiphophorus field. Using transgenesis, 
Schartl et al. (2010, this issue) have now 
built a bridge from the Xiphophorus to 
the medaka system by expressing the 
Xmrk oncogene in medaka and thereby 
generating a tractable genetic melano-
ma model. In Xiphophorus, oncogenic 
Xmrk is specifically expressed in the 
pigment cells, and so Schartl and col-
leagues expressed the Xmrk gene under 
the pigment cell-specific promoter, mitf, 
in medaka. Hemizygous transgenic fish 
expressing Xmrk develop nevi, with some 
developing melanoma by 6 months. 
Impressively, in homozygous transgenic 
Xmrk fish, all developed melanoma 
between 2 and 6 weeks of age. In this 
model, the mitf promoter also appears 
to express and generate tumors in the 
red and yellow pigment cell types (xan-
thophores and erythrophores, respec-
tively). The Xmrk melanomas are highly 
invasive and appear to be metastatic. 
Molecular analysis suggests that Xmrk 
medaka tumor melanomas are similar to 
Xmrk Xiphophorus tumors, in that both 
display activation of AKT signaling and 
enhanced activation of STAT5 signaling. 
MITF and BCL2 are also increased in the 
Xmrk medaka melanoma, providing in 
vivo evidence for a role of the Mitf–Bcl-2 
axis (McGill et al., 2002).
Where the transgenic Xmrk mela-
noma model becomes especially use-
ful is in the identification of genetic 
modifiers of the melanoma phenotype. 
Schartl and colleagues showed that the 
tumor spectrum and age of onset vary 
with genetic background. In the Carbio 
strain, Xmrk promoted pigment cell 
Oncogenes and tumor suppressor 
genes are highly conserved between 
zebrafish and humans, as are genes 
involved in angiogenesis, the cell cycle, 
apoptosis, and senescence. Importantly, 
zebrafish can develop a wide spec-
trum of tumors that share histopatho-
logical features with human cancers. 
The molecular pathways are also con-
served; for example, liver tumors in 
zebrafish share stage-specific gene 
expression signatures with liver tumors 
of the same histopathological grade in 
humans. Both zebrafish and medaka 
can be mutagenized with N-ethyl-N-
nitrosourea (ENU) for genetic screens, 
which allows the identification of spe-
cific phenotypes and subsequently 
their associated mutant genes by posi-
tional cloning. For example, spontane-
ous mutations and large-scale genetic 
screening in zebrafish and medaka have 
generated a wealth of mutations that 
give rise to specific pigment cell pheno-
types (Kelsh et al., 2004; Kelsh, 2004; 
White and Zon, 2008). In the cancer 
field, zebrafish ENU-based genetic 
screens have led to the identification of 
modifier mutations that enhance can-
cer susceptibility and determine tumor 
spectrum. In addition, insertional muta-
genesis in zebrafish has generated hun-
dreds of mutations in genetic screens, 
which have been rapidly identified by 
virtue of sequencing the insertion site. 
This method has led to the identifica-
tion of neuro fibromatosis type 2 and 
novel haploinsufficient ribosomal 
mutations that confer spontaneous 
neural tumors in the adult zebrafish. 
In an approach called TILLING, muta-
tions in specific genes are identified 
by sequencing from ENU mutagenized 
genomes, resulting in the identifica-
tion of mutations in tumor suppressor 
genes such as p53, PTEN, and APC, all 
of which confer tumor susceptibility 
however, is the identification of genetic 
modifiers of the nevi and melanoma 
phenotypes and the possible avenues of 
further research opened by the system 
described in the current study.
Using fish models to study cancer
Although the Xiphophorus hybrid mel-
anoma system can be viewed as the 
founding model for melanoma genet-
ics, for genome-wide genetic screens 
and dissecting the mechanisms of mel-
anocyte development and melanoma 
progression, the zebrafish and medaka 
model fish systems offer distinct advant-
ages (Patton and Zon, 2001; Kelsh et 
al., 2004; White & Zon, 2008). In con-
trast to the live-bearing Xiphophorus, 
in which the embryos are born after 
30 days of in utero development, the 
embryos of zebrafish and medaka are 
fertilized externally. This allows for 
analysis and visualization, as well as 
genetic or chemical modification, from 
the single-cell stage through embryo-
genesis to adulthood. Parents can be 
bred to generate hundreds of offspring 
each week. The genomic resources 
available place zebrafish next to mice 
and humans for comprehensive cov-
erage of vertebrate genomes, and the 
medaka genome is also available. The 
ability to control gene expression with 
morpholinos, RNA or DNA micro-
injection, transgenes, and genetic muta-
tions, coupled with sensitivity to small 
molecules (zebrafish embryos can eas-
ily be arrayed in 96-well plates), means 
that pathways relevant to cancer, such 
as cell cycle and signaling pathways, 
can be interrogated in the developing 
embryo and tested directly in the adult.
Already well established as 
a powerful model organism for 
studying development, the zebrafish 
is gaining momentum in the cancer 
field (Amatruda and Patton, 2008). 
Clinical Implications
•  Oncogenes and tumor suppressor genes are highly conserved between 
fish and humans.
•  In medaka and zebrafish there are a wealth of mutations that give rise to 
specific pigment cell phenotypes.
•  Transgenic medaka fish expressing the Xmrk oncogene develop nevi, 
with some developing melanoma by 6 months.
commentary
16 Journal of Investigative Dermatology (2010), Volume 130 
also activated, among other pathways, 
including the PLC-γ, STAT5, and FAK/
FYN pathways. When expressed in a 
p53-deficient background, the Xmrk-
induced tumor spectrum and age of 
onset are not affected, but at later stages 
there is a marked change, and the tumors 
suddenly begin to grow very rapidly. 
Despite the many pathways downstream 
of Xmrk, loss of p53 nevertheless appears 
to play an important role in melanoma 
progression, supporting the notion that 
the p53 pathway, despite the low rate of 
mutations in melanomas, has an impor-
tant role in melanoma progression.
opportunities for genetic  
and chemical screens
The power of this new Xmrk system 
lies in its potential for both genetic and 
chemical screens (Figure 1) (Patton and 
Zon, 2001; Zon and Peterson, 2005). 
Schartl and colleagues provide proof of 
principle that the genetic modifiers of 
the melanoma pathology can be identi-
fied in genetic screening, and although, 
with the exception of the p53 muta-
tion, the other mutations are currently 
unknown, this is a significant step for 
melanoma genetics. The rapid onset 
of Xmrk-induced nevi at 10 days and 
melanoma at 2–6 weeks (when the 
medaka fish are only about 0.3 and 1 
cm long, respectively) provides a unique 
opportunity for chemo therapeutic and 
chemopreventative screening. Zebrafish 
are increasingly being used in the drug 
discovery process, in part because the 
effects of the chemical compound can 
be assessed rapidly in a whole-animal 
context (Zon and Peterson, 2005). The 
recent development of BRAFV600E mouse 
melanoma models that demonstrate 
chemical and genetic control of mela-
noma progression provides an important 
rationale for screening for genetic muta-
tions and small molecules (or even com-
binations of small molecules) in animal 
models (Dankort et al., 2009; Dhomen 
et al., 2009; Goel et al., 2009). As the 
incidence of melanoma continues to 
rise and current chemo therapies remain 
generally ineffective against malignant 
melanoma (Gray-Schopfer et al., 2007), 
animal models such as this one provide 
an important means for dissecting the 
genetic and environmental factors that 
contribute to melanoma development 
Schartl and colleagues were able to 
directly test the role of a specific gene, 
p53, in tumor progression. The p53 path-
way appears to play a role in melanoma 
(Chin et al., 2006, Yu et al., 2009); how-
ever, mutations in p53 are relatively rare 
in melanoma compared with other tumor 
types. This may be in part because the 
CDKN2A locus is often mutated in mela-
noma and encodes both p16INK4A and 
p14ARF, controlling the INK4A-COK416-
RB and ARF-MDM2-p53 axes, respec-
tively (Chin et al., 2006). In mice, muta-
tions in p53 can cooperate with RAS to 
promote melanoma formation (Chin et 
al., 2006), and in zebrafish, BRAFV600E is 
sufficient to promote nevi, but requires 
loss of p53 for progression to melanoma 
(Patton et al., 2005). In contrast, onco-
genic Xmrk in medaka is sufficient to 
promote melanoma formation, possibly 
because in addition to mitogen-activated 
protein kinase-pathway signaling, the 
phosphoinositide 3-kinase pathway is 
tumors of all three pigment cells, as well 
as rare uveal melanomas. In the CabR’ 
genetic background, melanoma was 
rare and almost all tumors developed 
from the red and yellow pigment cells. 
These tumors were largely exophytic, 
with invasion seen only in the termi-
nal stages. In contrast, in the HB32C 
genetic background, almost all tumors 
were endophytic, invasive melanoma. 
In another line, the albino (i-3) strain, 
internal melanomas developed, in addi-
tion to a high percentage of uveal mela-
noma. Presuming the fish lines develop 
melanocytes and other pigment cells in 
a similar way, the genetic differences 
between the lines appear to account for 
the varied pigment cell tumor pheno-
types and provide strong evidence for 
how background polymorphisms can 
have a profound effect on cancer biol-
ogy within individuals.
Although the genetic differences in 
background have yet to be identified, 
Figure 1. the Xmrk medaka model provides an opportunity to identify genetic and chemical modifiers 
that suppress or enhance the nevi and melanoma phenotypes. In the mitf-Xmrk medaka melanoma model, 
hemizygous Xmrk fish give rise to progeny that are 25% wild type, 50% hemizygous for Xmrk (Xmrk/+), and 
25% homozygous for Xmrk (Xmrk/Xmrk; salmon-colored panels). By 10 days of development, homozygous 
Xmrk/Xmrk larvae express ectopic pigmentation (fish-nevi), and by 2–6 weeks of age, these fish develop 
melanoma. In the hemizygous Xmrk medaka, ectopic pigmentation develops by 6 weeks, and tumors 
develop by 6 months. Melanomas, or other pigmented tumors, are not observed in wild-type medaka fish. 
Schartl and colleagues (2010, this issue) provide evidence that genetic modifiers (M) that alter tumor biology, 
such as those in background variance or ENU mutations, can be identified (red panels). In these examples, 
mutations in Xmrk/Xmrk fish affect tumor progression (M; e.g., nevi, but not melanoma development); in 
Xmrk/+ fish, modifiers affect tumor spectrum (M1; e.g., uveal melanoma), tumor progression (M2; e.g., 
tumor size), or tumor pathology (M3; e.g., endophytic versus exophytic melanoma). The rapid onset of fish-
nevi and melanoma also allows for screening for small molecules that alter tumor characteristics. Young 
medaka fish can easily fit into 24- or 6-well plates, each with a different compound (Cpd) dissolved in the 
water. In these examples, Cpd3 prevents the onset of Xmrk/Xmrk-induced fish nevi in 10-day-old medaka; 
CpdB prevents development of melanoma in 6-week-old Xmrk/Xmrk medaka.
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of BRAF mutation and p53 inactivation 
during transformation of a subpopulation of 
primary human melanocytes. Am J Pathol 
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and progression, as well as identifying 
the drugs and new drug-like leads that 
can target this devastating disease.
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Sun-Sensitizing Effects of PKCε Shine 
on Multiple Mouse Strains
Mitchell F. Denning1
Like many skin phenotypes, susceptibility to carcinogenesis is profoundly influ-
enced by genetic background. Sand et al. (this issue) explored the sensitizing 
effects of epidermal protein kinase C ε (PKCε)expression in the hairless SKH-1 
mouse strain commonly used in UV carcinogenesis studies. They reported that 
PKCε overexpression profoundly sensitized these mice to UV skin carcinogenesis 
and activated oncogenic pathways similar to those reported in FVB/N mice.
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Anyone who has witnessed the diverse 
shades of sunburned skin on dis-
play at the beach can appreciate the 
importance of genetic background on 
the response of skin to UV radiation. 
Likewise, invest igators characterizing 
transgenic mice are aware of the impor-
tance of genetic background on phe-
notype because strain-specific effects 
are frequently reported. Differences in 
mouse strain susceptibility to carcino-
genesis, including UV skin carcinogen-
esis, are well known, and the genetic 
loci responsible for some of the differ-
ences have been identified, including 
some not related to skin pigmentation. 
The study by Sand and colleagues 
(2010, this issue) examines the sensitiz-
ing effects of protein kinase C ε (PKCε) 
overexpression on UV carcinogenesis in 
two mouse strains, FVB/N and SKH-1. 
Their findings highlight the potent effect 
of PKCε in enhancing skin carcinogen-
esis regardless of genetic background 
and shed light on the potential signal-
ing pathways involved.
PKcε and skin carcinogenesis
The PKC family of serine/threonine 
protein kinases occupies a central 
node in numerous growth factor and 
hormone receptor signal transduction 
pathways. These kinases have also been 
studied extensively as targets of the 
mouse skin tumor promoter, TPA, which 
is commonly used in “two-stage” mouse 
skin chemical carcinogenesis studies. 
Keratinocytes express at least five PKC 
isoforms (α, δ, ε, η, and ζ), each with 
a unique function in normal epidermal 
biology. Recent studies have focused on 
understanding biological functions of 
the individual PKC isoforms in UV skin 
carcinogenesis and identifying substrates 
relevant to these functions.
Verma and co-workers at the 
University of Wisconsin–Madison have 
generated and characterized trans-
genic mice expressing individual PKC 
isoforms in their epidermis under the 
control of the K14 promoter. These stud-
ies have been instrumental in clarifying 
the divergent effects of PKC isoforms on 
